Literature DB >> 11507230

No selection for CCR5 coreceptor usage during parenteral transmission of macrophagetropic syncytium-inducing human immunodeficiency virus type 1.

F A Koning1, D Schols, H Schuitemaker.   

Abstract

In two cases of parenteral transmission of human immunodeficiency virus type 1 (HIV-1) syncitium-inducing (SI) variants, we previously observed selection for macrophagetropic variants. Although infection of macrophages is generally mediated via CCR5, we found no selection for SI variants that could use CCR5 as coreceptor in addition to CXCR4, suggesting that features other than coreceptor usage account for the macrophagetropism of these transmitted SI HIV-1 variants.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11507230      PMCID： PMC115130          DOI： 10.1128/jvi.75.18.8848-8853.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  38 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

Authors:  J M Lange; C A Boucher; C E Hollak; E H Wiltink; P Reiss; E A van Royen; M Roos; S A Danner; J Goudsmit
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

4.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

5.  Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

Authors:  S H Weiss; J J Goedert; S Gartner; M Popovic; D Waters; P Markham; F di Marzo Veronese; M H Gail; W E Barkley; J Gibbons
Journal:  Science       Date:  1988-01-01       Impact factor: 47.728

6.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Biologic features of HIV-1 that correlate with virulence in the host.

Authors:  C Cheng-Mayer; D Seto; M Tateno; J A Levy
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728
View more
  6 in total

1.  Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.

Authors:  Eric G Meissner; Karen M Duus; Feng Gao; Xiao-Fang Yu; Lishan Su
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

Review 2.  When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration?

Authors:  Italo Mocchetti; Lee A Campbell; G Jean Harry; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-15       Impact factor: 4.147

3.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.

Authors:  Evelien H B Stalmeijer; Ronald P Van Rij; Brigitte Boeser-Nunnink; Janny A Visser; Marloes A Naarding; Dominique Schols; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.

Authors:  Elaine R Thomas; Rebecca L Dunfee; Jennifer Stanton; Derek Bogdan; Joann Taylor; Kevin Kunstman; Jeanne E Bell; Steven M Wolinsky; Dana Gabuzda
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

6.  Understanding the HIV coreceptor switch from a dynamical perspective.

Authors:  Christel Kamp
Journal:  BMC Evol Biol       Date:  2009-11-30       Impact factor: 3.260
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.